Treatment of benign bone lesions with an injectable biphasic bone substitute
Kevin Döring(Vienna General Hospital), Catharina Chiari(Orthopaedic Hospital Speising), Stephan Puchner(Vienna General Hospital), Reinhard Windhager(Medical University of Vienna), Colleen Rentenberger(Vienna General Hospital), Janina Patsch(Medical University of Vienna), Alexander Kolb(Medical University of Vienna)
Cited by 3
Related Papers
Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures
|Journal of Bone and Mineral Research|2012|436
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419
Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures
|Journal of Bone and Mineral Research|2013|324
Transcriptional regulator PRDM12 is essential for human pain perception
|Nature Genetics|2015|172